Mothaffar Rimawi, M.D.
Mothaffar Rimawi, M.D.
Professor, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Verified email at
Cited by
Cited by
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ...
Cancer research 68 (3), 826-833, 2008
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615, 2012
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ...
Cancer research 73 (15), 4885-4897, 2013
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2 …
B Dave, I Migliaccio, MC Gutierrez, MF Wu, GC Chamness, H Wong, ...
Journal of Clinical Oncology 29 (2), 166, 2011
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation
YC Wang, G Morrison, R Gillihan, J Guo, RM Ward, X Fu, MF Botero, ...
Breast Cancer Research 13 (6), 1-19, 2011
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 …
MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ...
Journal of clinical oncology 31 (14), 1726, 2013
Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy
G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ...
Journal of the National Cancer Institute 99 (9), 694-705, 2007
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
MF Rimawi, PB Shetty, HL Weiss, R Schiff, CK Osborne, GC Chamness, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Targeting HER2 for the treatment of breast cancer
MF Rimawi, R Schiff, CK Osborne
Annual review of medicine 66, 2015
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor–positive, HER-2/neu-positive breast cancer
S Massarweh, CK Osborne, S Jiang, AE Wakeling, M Rimawi, SK Mohsin, ...
Cancer research 66 (16), 8266-8273, 2006
Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ...
Cancer chemotherapy and pharmacology 56 (1), 10-20, 2005
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
S Aebi, S Gelber, SJ Anderson, I Láng, A Robidoux, M Martín, ...
The lancet oncology 15 (2), 156-163, 2014
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
C Huang, CC Park, SG Hilsenbeck, R Ward, MF Rimawi, Y Wang, J Shou, ...
Breast cancer research 13 (4), 1-15, 2011
Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial
J Nangia, T Wang, C Osborne, P Niravath, K Otte, S Papish, F Holmes, ...
Jama 317 (6), 596-605, 2017
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ...
Breast cancer research and treatment 136 (3), 795-804, 2012
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti–IGF-IR therapy
BC Litzenburger, CJ Creighton, A Tsimelzon, BT Chan, SG Hilsenbeck, ...
Clinical Cancer Research 17 (8), 2314-2327, 2011
Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2–positive breast cancer and …
RA Freedman, RS Gelman, JS Wefel, ME Melisko, KR Hess, RM Connolly, ...
Journal of Clinical Oncology 34 (9), 945, 2016
TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases
RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ...
Journal of Clinical Oncology 37 (13), 1081, 2019
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ...
Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
MF Rimawi, LS Wiechmann, YC Wang, C Huang, I Migliaccio, MF Wu, ...
Clinical Cancer Research 17 (6), 1351-1361, 2011
The system can't perform the operation now. Try again later.
Articles 1–20